title: The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors.
abstract: In trial no. 22811 on a randomized comparison of multiple fractions per day (MFD), with or without misonidazole, to conventional fractionation in advanced head and neck cancer, a large number (523) of patients was entered in a short period of time. No differences in treatment results were obtained, but the study created an important database, allowing for detailed evaluation of the most important factors influencing prognosis. In univariate analysis, factors significantly influencing survival and locoregional control were: performance status, histological differentiation, tumor site, tumor and nodal staging, and tumoral and nodal volume. In multivariate analysis, significant factors for survival were nodal involvement, tumor stage, performance status, and tumor site. Significant factors for locoregional control were nodal involvement and total tumor burden. This analysis suggests that total tumor burden (volume) should be included in the interpretation of treatment results in head and neck cancer.
authors.affiliation: Radiotherapy Department, University Hospital, Gasthuisberg, Leuven, Belgium.
authors.forename: W
authors.initials: W
authors.lastname: Van den Bogaert
authors.forename: E
authors.initials: E
authors.lastname: van der Schueren
authors.forename: J C
authors.initials: JC
authors.lastname: Horiot
authors.forename: M
authors.initials: M
authors.lastname: De Vilhena
authors.forename: S
authors.initials: S
authors.lastname: Schraub
authors.forename: V
authors.initials: V
authors.lastname: Svoboda
authors.forename: G
authors.initials: G
authors.lastname: Arcangeli
authors.forename: M
authors.initials: M
authors.lastname: de Pauw
authors.forename: M
authors.initials: M
authors.lastname: van Glabbeke
mesh_terms: D003131:Combined Modality Therapy; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008920:Misonidazole / Q000627:therapeutic use*; D011379:Prognosis; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D015996:Survival Rate
chemical_list: D011838:Radiation-Sensitizing Agents; D008920:Misonidazole